Results 31 to 40 of about 2,114,452 (380)
Ability of vaccine strain induced antibodies to neutralize field isolates of caliciviruses from Swedish cats [PDF]
, 2015 Background: Feline calicivirus (FCV) is a common cause of upper respiratory tract disease in cats worldwide. Its characteristically high mutation rate leads to escape from the humoral immune response induced by natural infection and/or vaccination and ...
Berndtsson, Louise Treiberg +5 more
core +2 more sources
Varicella: to vaccinate or not to vaccinate? [PDF]
Archives of Disease in Childhood, 1998 Editor,—I am in complete agreement with Dr Aebi that strategies for delivering varicella vaccine effectively are critical to the success of immunisation programmes.1 In the USA great efforts are being made in this direction. Nevertheless, despite the licensure of varicella vaccine for routine use in the United …
openaire +5 more sources
Vaccine hesitancy: the next challenge in the fight against COVID-19
European Journal of Epidemiology, 2020 Vaccine hesitancy remains a barrier to full population inoculation against highly infectious diseases. Coincident with the rapid developments of COVID-19 vaccines globally, concerns about the safety of such a vaccine could contribute to vaccine hesitancy.
A. Dror +7 more
semanticscholar +1 more source
MODELO DE IMPACTO EM SAÚDE PÚBLICA DA INTRODUÇÃO DE UMA VACINA HÉRPES-ZOSTER RECOMBINANTE NO BRASIL
Brazilian Journal of Infectious Diseases, 2022 Introdução: O herpes-zoster (HZ) manifesta-se normalmente em idosos ou indivíduos imunocomprometidos a partir da reativação do vírus varicela zoster latente.
Ru Han +4 more
doaj
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
New England Journal of Medicine, 2021 Background On July 30, 2021, the administration of a third (booster) dose of the BNT162b2 messenger RNA vaccine (Pfizer–BioNTech) was approved in Israel for persons who were 60 years of age or older and who had received a second dose of vaccine at least ...
Y. Bar-On +10 more
semanticscholar +1 more source
Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
New England Journal of Medicine, 2021 Background Efficacious vaccines are urgently needed to contain the ongoing coronavirus disease 2019 (Covid-19) pandemic of infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
J. Sadoff +26 more
semanticscholar +1 more source
Human Vaccines & Immunotherapeutics, 2017 A therapeutic vaccine for human Chagas disease is under development by the Sabin Vaccine Institute Product Development Partnership. The aim of the vaccine is to significantly reduce the parasite burden of Trypanosoma cruzi in humans, either as a ...
Christopher A. Seid +15 more
doaj +1 more source
Comprehensive Flow Cytometry Analysis of PEI-Based Transfections for Virus-Like Particle Production
Research, 2020 The generation of stable clones for biomolecule production is a common but lengthy and labor-intensive process. For complex molecules, such as viruses or virus-like particles (VLPs), the timeline becomes even more cumbersome. Thus, in the early stages of
Daniel J. Blackstock +7 more
doaj +1 more source
Evidence for cross-protection but not type-replacement over the 11 years after human papillomavirus vaccine introduction [PDF]
, 2019 Examination of cross-protection and type replacement after human papillomavirus (HPV) vaccine introduction is essential to guide vaccination recommendations and policies.
Bernstein, David I. +5 more
core +1 more source
Emerging concepts in the science of vaccine adjuvants
Nature reviews. Drug discovery, 2021 Adjuvants are vaccine components that enhance the magnitude, breadth and durability of the immune response. Following its introduction in the 1920s, alum remained the only adjuvant licensed for human use for the next 70 years.
B. Pulendran +2 more
semanticscholar +1 more source